A groundbreaking clinical trial set to begin this year in Victoria, British Columbia, aims to utilize artificial intelligence (AI) to transform prostate cancer radiation therapy. The trial, known as ADAPT-25 (Artificial Intelligence-Driven Adaptive Prostate Stereotactic Radiation Therapy), seeks to reduce the standard treatment of 20 to 40 sessions to just two large treatments, significantly decreasing side effects and wait times.
Leading the trial are radiation oncologists Dr. Abe Alexander and Dr. Winkle Kwan, who hope to enhance the treatment process and ultimately improve the cure rate and minimize side effects. The goal is to provide patients with 100% cure rates while delivering zero side effects and reducing the number of visits required for treatment.
Previous research conducted in 2017, through a trial named ASSERT, demonstrated promising results. Half of the 80 patients involved received five fractions of stereotactic ablative radiotherapy (SABR), a more advanced technology with higher-intensity doses. The trial revealed that patients tolerated the treatment well, experienced equal or fewer side effects, and reported an improved quality of life.
The ADAPT-25 trial will build upon this success by employing an AI algorithm to enhance precision during radiation treatment. By targeting cancer cells using AI, therapists can leverage advanced imaging to track the motion of the prostate in real-time, making necessary adjustments and optimizing treatment efficacy. The algorithm can analyze imaging data in ways that surpass human capabilities, suggesting changes to adapt treatment plans in real-time and maximize effectiveness.
The clinical trial, expected to commence later this year, will involve 100 patients who have not undergone surgery or radiation as the primary treatment for their prostate cancer. Researchers will compare the benefits and challenges of the five-fraction treatment to the new two-fraction treatment regimen.
The implications of this trial extend beyond Victoria, as the previous radiation treatment approach has already become the standard in various centers across British Columbia. With the success of the previous trial in mind, the medical community aims to pioneer new advancements in precision through the use of AI algorithms.
Supported by approximately $500,000 in donations through the B.C. Cancer Foundation, the ADAPT-25 trial holds promise for both patients and healthcare providers. By harnessing the power of AI and advanced imaging technologies, this innovative approach to prostate cancer treatment has the potential to revolutionize the field, providing patients with more effective, efficient, and personalized care.
FAQ Section:
Q: What is the ADAPT-25 clinical trial?
A: The ADAPT-25 trial, set to begin in British Columbia, aims to use artificial intelligence (AI) to transform prostate cancer radiation therapy. It seeks to reduce the standard treatment of 20 to 40 sessions to just two large treatments, decreasing side effects and wait times.
Q: Who is leading the trial?
A: The trial is led by radiation oncologists Dr. Abe Alexander and Dr. Winkle Kwan.
Q: What is the goal of the trial?
A: The goal is to enhance the treatment process, improve the cure rate, minimize side effects, and reduce the number of visits required for treatment.
Q: What were the results of the previous trial named ASSERT?
A: The ASSERT trial demonstrated promising results, with patients tolerating the treatment well, experiencing equal or fewer side effects, and reporting an improved quality of life.
Q: How will the ADAPT-25 trial build upon the previous success?
A: The ADAPT-25 trial will employ an AI algorithm to enhance precision during radiation treatment. It will use advanced imaging to track the motion of the prostate in real-time, making necessary adjustments and optimizing treatment efficacy.
Q: How many patients will be involved in the ADAPT-25 trial?
A: The trial will involve 100 patients who have not undergone surgery or radiation as the primary treatment for their prostate cancer.
Q: What will be compared in the trial?
A: Researchers will compare the benefits and challenges of the five-fraction treatment to the new two-fraction treatment regimen.
Q: What are the implications of this trial?
A: The trial aims to pioneer new advancements in precision through the use of AI algorithms. If successful, it has the potential to revolutionize prostate cancer treatment.
Key Terms:
– AI: Artificial Intelligence
– ADAPT-25: Artificial Intelligence-Driven Adaptive Prostate Stereotactic Radiation Therapy
– SABR: Stereotactic Ablative Radiotherapy
Related links:
– B.C. Cancer Foundation
– National Cancer Institute
– American Cancer Society
The source of the article is from the blog krama.net